Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1114 | 1114 | 1177 | 1265 | 1641 | 4050 |
Fund Return | 11.37% | 11.37% | 17.68% | 8.15% | 10.41% | 15.01% |
Place in category | 1128 | 1128 | 2183 | 706 | 922 | 35 |
% in Category | 39 | 39 | 74 | 32 | 54 | 4 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fundsmith Equity Feeder Class R EUR | 8.9B | 11.23 | 7.64 | 14.46 | ||
Fundsmith Equity Feeder R EUR Inc | 8.9B | 11.24 | 7.64 | 14.47 | ||
Fundsmith Equity Fund Feeder I EURi | 8.9B | 11.41 | 8.33 | 15.19 | ||
Fundsmith Equity Fund Feeder I EURe | 8.9B | 11.41 | 8.21 | 15.14 | ||
Fundsmith Equity Fund Feeder T EURt | 8.9B | 11.37 | 8.18 | 15.03 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cap Group New Perspective lux N | 13.49B | 7.64 | 3.02 | - | ||
Capital Group New Perspective Funde | 13.49B | 8.02 | 4.73 | 10.38 | ||
Cap Group New Perspective lux C EUR | 13.49B | 8.20 | 5.30 | - | ||
Capital Group New Perspective Funbe | 13.49B | 7.78 | 3.68 | 9.31 | ||
Cap Group NewPerspective lux ZL EUR | 13.49B | 8.03 | 4.70 | 10.35 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 9.79 | 883.1 | -0.39% | |
Microsoft | US5949181045 | 9.35 | 406.32 | +1.82% | |
L'Oreal | FR0000120321 | 6.32 | 440.25 | +1.06% | |
Stryker | US8636671013 | 5.26 | 335.66 | -0.44% | |
Meta Platforms | US30303M1027 | 5.19 | 443.29 | +0.43% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Neutral | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review